Diagnostic Value of Circulating PIGF in Combination with Flt-1 in Early Cervical Cancer  

作　　者：Shou-hua YANG Xiao-ling WANGt Jing CAI Shao-hai WANG 

机构地区：[1]Deparment of Obstetrics and Gynecology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China

出　　处：《Current Medical Science》2020年第5期973-978,共6页当代医学科学（英文）

基　　金：This work was supported by the National Natural Science Foundation of China(No.81202063).

摘　　要：The utility of placental growth factor(PIGF)and its receptor VEGFR-1(Flt-1)as biomarkers for cervical cancer has not been clarified yet.To address this issue,we investigated the levels of soluble PIGF(sPIGF)and soluble Flt-1(sFlt-1)in the serum from patients with early cervical cancer,cervical intraepithelial neoplasia(CIN)and controls in this study.sPIGF and sFlt-1 were detected in 44 preoperative patients with cervical cancer,18 cases with CIN,and 20 controls by ELISA.It was found that both sPIGF and sFlt-1 were significantly increased in the cervical cancer group as compared with those in CIN and control groups.sPIGF presented a high diagnostic ability of cervical cancer,with a sensitivity of 61.36%and a specifcity of 89.47%;and sFlt-1 with a sensitivity of 50.00%and a specifcity of 92.I 1%。Importantly,the combined use of sPIGF and sFlt-1 could increase the diagnostic rate of cervical cancer,with a sensitivity of 70.45%and a specificity of 92.11%.These results indicated that both sPIGF and sFlt-1 in circulation can serve as possible valuable diagnostic biomarkers for cervical cancer,and the combined use of them can be more valuable to diagnose the patients with early cervical cancer.

关 键 词：cervical cancer placental growth factor SFLT-1 BIOMARKER 

分 类 号：R71[医药卫生—妇产科学]